With COVID-19 highlighting gaps in diversity and inclusion in clinical trials, the oncology community is more committed than ever to leverage our collective expertise and innovative solutions and technologies to create the change we want to see.Īs the key theme of ASCO ‘22, there were many opportunities to share ways to enhance equitable cancer care with fellow stakeholders.
#Destiny 2 trials report trial
With so many advancements, it’s hard to select a few, but below are some of the interesting topics and trends highlighted at this year’s meeting.įor decades, the industry has worked to expand trial access and participation to engage diverse and underserved patient populations affected by cancer, but it has been a complex and multi-pronged challenge. From global oncology R&D trends to the role of real world evidence in trials to patient-centered approaches, the industry has put a great amount of investment in cancer care and drug development, which was emphasized at ASCO.
Participating in or attending key oral sessions, clinical science symposiums, poster presentations or simply having coffee break chats with colleagues across regions and disciplines, it’s obvious we all shared a passion to elevate innovation in cancer care.įrom a R&D perspective, we are excited to leave ASCO with useful learnings, best practices and opportunities to continue collaborative conversations with stakeholders to further accelerate the innovative oncology breakthroughs, ensuring they are reaching patients faster to make a genuine difference in their lives and health. Attending the American Society of Clinical Oncology (ASCO) annual meeting this year, we had the chance to meet up with others in research and development (R&D), service partners and clinicians to participate in discussions about notable advancements in global cancer care over the last year.
0 kommentar(er)
